March 2024 PROTEOMIMETIC POLYMERS SHOW ANTI-ANGIOGENIC ACTIVITY IN AMD MOUSE MODELFeaturing: Gregory W. Schwartz, PhD, and Jeremy A. Levine, MD, PhD
A new study featuring Gregory W. Schwartz, PhD, and Jeremy A. Levine, MD, PhD, both of Northwestern Medicine Ophthalmology, explores a potential breakthrough in the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of irreversible vision loss. This research team developed protein-like polymers (PLPs) that effectively inhibit the abnormal growth of blood vessels associated with nAMD. These PLPs, particularly the block copolymer Co-P1, reduced choroidal sprouting and laser-induced choroidal neovascularization in ex vivo and in vivo mouse models. The PLPs demonstrated resistance to degradation and had a prolonged half-life after injection. This study offers hope for a novel and more effective treatment for nAMD. Read the study on Science Advances. |
Gregory W. Schwartz, PhD, the Derrick T. Vail Professor of Ophthalmology
Refer a PatientNorthwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients.
|